All In Biotech

Drug Trial Radar · NCT03946670

A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).

A Randomized, Double-blind, Placebo-controlled Phase II Multi-center Study of Intravenous MBG453 Added to Hypomethylating Agents in Adult Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria

Last checked: Nov 20, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 127 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

127

Actual

Start

Jun 4, 2019

Primary completion

Apr 26, 2022

Study completion Jul 15, 2024

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 13, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase II was a multicenter, randomized, two-arm parallel-group, double-blind, placebo-controlled study of MBG453 or placebo added to hypomethylating agents (azacitidine or decitabine) in adult subjects with IPSS-R intermediate, high or very high risk myelodysplastic syndrome (MDS) not eligible for Hematopoietic Stem Cell Transplant (HSCT) or intensive chemotherapy.

Conditions

  • Myelodysplastic Syndromes

Interventions

  • MBG453Drug

    MBG453 is being administered i.v.

  • PlaceboDrug

    Placebo is being administered i.v.

  • Hypomethylating agentsDrug

    Decitabine is being administered i.v. Azacitidine is being administered i.v or s.c.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete Remission (CR) RateTime frame: average of 7 months
  2. Progression Free Survival (PFS)Time frame: approx. 32 months

Locations

48 sites in 17 countries. Site status is shown where the registry gives one.

  • City Of Hope National Med Center

    Duarte, California

  • City of Hope National Medical Center Medical Oncology & Therapeutic

    Duarte, California

  • Yale University School Of Medicine

    New Haven, Connecticut

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • The Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • Ohio State Comprehensive Cancer Center James Cancer Hospital

    Columbus, Ohio

  • Mary Crowley Cancer Research

    Dallas, Texas

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Brasschaat, Belgium

  • Novartis Investigative Site

    Leuven, Belgium

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Québec, Quebec, Canada

  • Novartis Investigative Site

    Brno, Czechia

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Toulouse, France

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Leipzig, Saxony, Germany

  • Novartis Investigative Site

    Alexandroupoli, Greece

  • Novartis Investigative Site

    Larissa, Greece

  • Novartis Investigative Site

    Pátrai, Greece

  • Novartis Investigative Site

    Hong Kong, Hong Kong

  • Novartis Investigative Site

    Nyíregyháza, Hungary

  • Novartis Investigative Site

    Debrecen, Hajdu Bihar Megye, Hungary

  • Novartis Investigative Site

    Florence, FI, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Rozzano, MI, Italy

  • Novartis Investigative Site

    Reggio Calabria, RC, Italy

  • Novartis Investigative Site

    Roma, RM, Italy

  • Novartis Investigative Site

    Gifu, Japan

  • Novartis Investigative Site

    Osaka, Japan

  • Novartis Investigative Site

    Fukuoka, Fukuoka, Japan

  • Novartis Investigative Site

    Fukushima, Fukushima, Japan

  • Novartis Investigative Site

    Isehara, Kanagawa, Japan

  • Novartis Investigative Site

    Kumamoto, Kumamoto, Japan

  • Novartis Investigative Site

    Sendai, Miyagi, Japan

  • Novartis Investigative Site

    Nagasaki, Nagasaki, Japan

  • Novartis Investigative Site

    Bunkyo Ku, Tokyo, Japan

  • Novartis Investigative Site

    Seoul, South Korea

  • Novartis Investigative Site

    Seoul, Korea, South Korea

  • Novartis Investigative Site

    Málaga, Spain

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.